Assessment of Serum Apelin Level in Iraqi Type 2 Diabetic Nephropathy Patients

Authors

  • Raghad Raheem department of chemistry, college of sciences, Al-Nahrain University, Jadriya, Baghdad, Iraq
  • Alaa Hussein J. Al-Qaisi department of chemistry, college of sciences, Al-Nahrain University, Jadriya, Baghdad, Iraq
  • Salam Mohammed Department of Chemical and Petrochemical Engineering, College of Engineering and Architecture, University of Nizwa, Nizwa, Oman

Keywords:

Adipokines, Apelin, Diabetes mellitus, Diabetic nephropathy, Type2 diabetes mellitus

Abstract

The present study is investigated the relationship between Apelin concentration and various biochemical parameters in patients with type 2 diabetic nephropathy. A total of 30 patients diagnosed with Diabetic Nephropathy at Al-Yarmouk and Al-Karama teaching hospitals were included in the study and compared to 40 healthy individuals forming the control group. The study was identified a significant increase in Apelin concentration among patients with type 2 diabetic nephropathy, compared to the control group. Additionally, various biochemical parameters were analyzed, and a strong correlation was found between their concentrations and Apelin levels. Considerable elevation of serum nitrogen compounds like urea and creatinine, as well as fasting blood glucose and glycated hemoglobin (HbA1c) were observed  in the type 2 diabetic nephropathy patients. A positive correlation between Apelin and both creatinine and glycated hemoglobin levels was observed. Conversely, a negative correlation was observed between Apelin and the glomerular filtration rate (GFR), indicating potential implications for kidney function in these patients. These findings emphasize the significance of monitoring Apelin concentration along with other biochemical variables as essential indicators for the management and understanding of type 2 diabetic nephropathy. Further research in type 2 diabetic nephropathy  could offer valuable insights into potential interventions and treatment strategies for improving patient outcomes.

References

American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetesd2021. Diabetes Care 2021;44(Suppl. 1):S152S33

Jawad, A.H.; Alsayed, R.; Emad, M.; Ibrahim, A.E.; Al-Qaisi, Z.; Hairunisa, N.; Yousif, E.; “Investigation of The Lipid Profile Level Fluctuation in Diabetes Mellitus Patients in Iraq”. Res. J. Pharm. Biol. Chem. Sci., 7 (6): 1331–1335, 2016.

Forst, T.; Mathieu, C.; Giorgino, F.; Wheeler, D.C.; Papanas, N.; “New Strategies To Improve Clinical Outcomes for Diabetic Kidney Disease”. BMC Med., 20 (1):1–15, 2022.

Rando, M.M.; Guthoff, M.; Tiwari, V.; Biscetti, F.; “Editorial: Diagnosis, Prevention and Treatment in Diabetic Nephropathy”. Front. Endocrinol. (Lausanne)., 13 (9): 1–3, 2022.

Sugahara, M.; Pak, W.L.W.; Tanaka, T.; Tang, S.C.W.; Nangaku, M.; “Update on Diagnosis, Pathophysiology, and Management of Diabetic Kidney Disease”. Nephrology, 26 (6): 491–500, 2021.

Read, C.; Nyimanu, D.; Williams, T.L.; Huggins, D.J.; Sulentic, P.; “International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of The Apelin Receptor With a Recommendation That Elabela/Toddler is a Second Endogenous Peptide Ligand”. Pharmacol. Rev., 71 (4): 467–502, 2019

Rüster, C.; Wolf, G.; “Adipokines Promote Chronic Kidney Disease” . Nephrol. Dial. Transplant., 28 (4): 8–14, 2013.

İçen, G.; Dağlıoğlu, G.; Evran, M.; “Evaluation of Apelin-13 Levels in Patients With Diabetic Nephropathy”. Int. Urol. Nephrol., 55 (2): 345–353, 2023.

Day, R.T.; Cavaglieri, R.C.; Feliers, D.; “Apelin Retards The Progression of Diabetic Nephropathy”. Am. J. Physiol. - Ren. Physiol., 304 (6);788–800, 2013.

Estienne, A.; Bongrani, A.; Reverchon, M.; Ramé, C.; “Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models”. Int. J. Mol. Sci., 20 (18): 4431-4476 2019.

Bhatia, K.; Misra, P.; Singh, A.; Mukherjee, B.; Ambade, V.N.; “Study of Blood Urea Nitrogen (BUN), Serum Creatinine In Diabetic and Non-Diabetic Patients In A Tertiary Care Hospital”. Int. J. Med. Biomed. Stud., 3 (4): 180-186, 2019.

Chen, L.; Zhu, Z.; Ye, S.; Zheng, M.; “The Serum Uric Acid to Serum Creatinine Ratio is an Independent Risk Factor for Diabetic Kidney Disease”. Diabetes, Metab. Syndr. Obes. Targets Ther., 15 (11): 3693–3703, 2022.

Wu, Y.; Wang, Y.; Zhang, J.; Zhang, R.; Zhao L.; “Early-onset of Type 2 Diabetes Mellitus Is a Risk Factor For Diabetic Nephropathy Progression: A Biopsy-based Study”. Aging (Albany. NY)., 13 (6): 8146–8154, 2021.

Helmy, M.; Hamdy, N.; El-Ghaffar, N.; “Connection Between The Plasma Level of Apelin and Diabetic Nephropathy in Type 2 Diabetic Patients. A Case Control Study”. Indian J. Endocrinol. Metab., 25 (5): 418–426, 2021.

El-Kafrawy, N.A.; Abo El-Hassan, M.H.; Nouh, M.Z.; Korany, M.A.; “Evaluation of Apelin Level in Type 2 Diabetic Patients with Peripheral Neuropathy and Nephropathy”; Med. J. Cairo Univ., 86 (9): 2303–2309, 2018.

Downloads

Published

2023-09-18

Issue

Section

Articles

How to Cite

[1]
“Assessment of Serum Apelin Level in Iraqi Type 2 Diabetic Nephropathy Patients”, ANJS, vol. 26, no. 3, pp. 18–23, Sep. 2023, Accessed: May 11, 2024. [Online]. Available: https://anjs.edu.iq/index.php/anjs/article/view/2570